Effect of an Environmental Health Education Program on Pregnant Women in Order to Reduce Endocrine Disruptor Exposition

January 28, 2021 updated by: Poitiers University Hospital

Effect of an Environmental Health Education Program on Pregnant Women in Order to Reduce Endocrine Disruptor Exposition : Controled Randomized Trial on Primary Prevention

Endocrine disruptors are known as a cancer cause. On pregnant women, it can induce major foetal pathology and impact growth.

Among those molecules, bisphenol-A (BPA) is a plasticizer that can be found on cans and water.

Through a prevention program, the investigators tried to warned pregnant women on endocrine disruptors exposition risks. The goal here is to assess the effectiveness of this program on their fresh products consumption.

Study Overview

Study Type

Interventional

Enrollment (Actual)

267

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Poitiers, France, 86000
        • Centre Hospitalier Universitaire de Poitiers

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients over 18
  • Patients living in Poitiers or city around (near the immersive environment)
  • Patients on pregnancy and who declared their pregnancy to the authority
  • Patients who planned to give birth in Poitiers's hospital, Châtellerault's hospital or Clinique Fief de Grimoire, in Poitiers.
  • Patients giving her agreement

Exclusion Criteria:

  • Patients planning to move during the study
  • Patients under legal protection
  • Patients expecting twins
  • Patients unable to speak french
  • Patients willing to give birth in another hospital than those mentionned before

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Leaflet only
Women will only receive a leaflet about endocrine disruptor at home.
ACTIVE_COMPARATOR: non immersive program
In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
EXPERIMENTAL: immersive program
In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
program effectivness
Time Frame: During the pregnancy (second and third trimester)
Assessing the Effectiveness of the Prevention Program "My Home, My Health Environment" (consists of a series of workshop in the second and third trimesters of pregnancy) in an immersive environment or not, to evaluate the consumption of fresh products according to exposure endocrine disruptors (cans or industrial products).
During the pregnancy (second and third trimester)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
psychosocial aspects
Time Frame: During the pregnancy (second and third trimester)
Assess if the program impact any psychosocial aspects, this outcome will be determine with a psychosocial questionary (to do before and after the intervention for compare the results)
During the pregnancy (second and third trimester)
Urine concentration
Time Frame: During the pregnancy (second and third trimester)
Assess if the program has an impact on the urinary endocrine disruptors's concentrations, this outcome will be determine with samples of urine (to do before and after the intervention for comparate the results)
During the pregnancy (second and third trimester)
Milk concentration
Time Frame: After the birth of the child (first year)
Assess the milk endocrine disruptors's concentration difference between women exposed and unexposed to the program
After the birth of the child (first year)
foetal growth
Time Frame: After the birth of the child (first year)
Study the relation between endocrine disruptors expositions and foetal growth by merging PREVED and EDDS (a previous trial) datas.
After the birth of the child (first year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 19, 2017

Primary Completion (ACTUAL)

May 15, 2019

Study Completion (ACTUAL)

September 28, 2020

Study Registration Dates

First Submitted

June 26, 2017

First Submitted That Met QC Criteria

July 27, 2017

First Posted (ACTUAL)

July 31, 2017

Study Record Updates

Last Update Posted (ACTUAL)

January 29, 2021

Last Update Submitted That Met QC Criteria

January 28, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • PREVED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

3
Subscribe